IMPROVING EFFICIENCY OF ANTIOXIDANT AND CYTOPROTECTIVE THERAPY IN PATIENTS WITH NSAID-GASTROPATHY AND CONCOMITANT ISCHEMIC HEART DISEASE

. Non-steroidal anti-inflammatory drugs (NSAID) are remaining to be the gold standard of antiplatelet therapy for ischemic heart disease, but at the same time NSAID therapy is associated with a number of side effects and risks, among which the leading place is ranked by gastropathy. The aim of this study was to explore the ways in improving the effectiveness of the integrated therapy modification for patients who had gastropathy not associated with Helicobacter Pylori, and concomitant ischemic heart disease, by including Artemisia Argyi leaf extract. Materials and methods. The study involved 82 patients, who, depending on prescribed therapeutic schemes were divided into two groups: I (n=44) group took proton pump inhibitors in standard doses (standard therapy) and II group (n=38), who, in addition to the standard mode of the therapy took Artemisia Argyi leaf extract. The condition of gastric mucosal barrier was assessed by the serum content of N-acetylneuraminic acid and fucoproteins; oxidative stress activity was evaluated by serum TBA concentration and catalase activity. Results. The patients who took Artemisiae Argyi extract and the proton pump inhibitor therapy have demonstrated the increase in mucosal barrier resistance of the gastroduodenal area that was confirmed by reducing of N-acetylneuraminic acid in serum in 1.2 times (p<0.001) following 14 days and in 2 times (p<0.001) after 1.5 months compared to the baseline parameters; while serum fucoproteins increased in 1.4 times (p<0.05) and 1.9 times (p<0.001), respectively. Over 1.5 months of the therapy the content of serum TBA-reactants was 9.76±3.16 µmol/l, catalase – 3.05±0.44 IU/l. Conclusion. The study has proven positive cytoprotective and antioxidant effect of Artemisiae Argyi leaf extract for patients with NSAID-induced gastropathy and is not associated with Helicobacter Pylori.